Brokerages forecast that Abeona Therapeutics Inc (NASDAQ:ABEO) will post $240,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $300,000.00. Abeona Therapeutics posted sales of $260,000.00 in the same quarter last year, which suggests a negative year over year growth rate of 7.7%. The business is scheduled to issue its next earnings report on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full-year sales of $240,000.00 for the current year, with estimates ranging from $800,000.00 to $900,000.00. For the next year, analysts forecast that the business will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Abeona Therapeutics.
A number of research firms have weighed in on ABEO. Maxim Group reissued a “buy” rating and issued a $35.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, February 7th. Jefferies Group restated a “buy” rating and set a $28.00 price target on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. HC Wainwright set a $30.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Thursday, February 8th. ValuEngine upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $27.11.
Abeona Therapeutics (ABEO) opened at $13.95 on Wednesday. Abeona Therapeutics has a 12 month low of $4.55 and a 12 month high of $22.75.
WARNING: This article was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3227349/abeona-therapeutics-inc-abeo-expected-to-post-quarterly-sales-of-240000-00-2.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.